Innovative Targeted and Immune-Mediated Cancer Therapies
Pipeline
Developing first-in-class oral drug therapeutics with broad potential benefit for cancer patients
News
April 29,
2026
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
April 22,
2026
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
April 14,
2026
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Events
Tuesday,
December 3RD,
2024
at
9:00 AM
Eastern
Piper Sandler 36th Annual Healthcare Conference
Listen: Webcast
Thursday,
June 20TH,
2024
at
8:30 AM
Eastern
Amezalpat (TPST-1120) Global Randomized Phase 1b/2 Combination Study Update Call
Listen: Webcast
Download: Presentation [pdf]
Wednesday,
October 11TH,
2023
at
8:30 AM
Eastern
TPST-1120 Global Randomized Phase 1b/2 Combination Study Data Call
Listen: Webcast
Download: Presentation [pdf]